Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial position and governance. These moves demonstrate a strong commitment to the company's vision and strategic plan to commercialize a... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that subject to regulatory approval, it is proposing to issue 4 Million shares @ 0.71 per share to move $3.5 Million from its balance... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") The Company is pleased to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (" MYND " or the " Company "), a pioneering biopharmaceutical research and development company committed to advancing treatments for patients coping with chronic and acute neurological and inflammatory diseases, is delighted to announce the immediate appointment of Mr. John (Jay) Campbell as President and Chief... Read More

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (" MYND " or the " Company "), We are delighted to announce the appointment of Mynd Life Sciences current CEO and Director, the Hon. Dr. Lyle Oberg, E.C.A., as the Board Chair of Alberta Health Services (AHS). Dr. Oberg brings a distinguished career in both private practice and public service, having served as... Read More

Potential merger to create new industry leader. Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) (" MYND " or the " Company "), a pioneering biopharmaceutical research and development company dedicated to revolutionizing treatments for patients battling relentless neurological and inflammatory diseases, announces that it has taken a definitive step forward by... Read More

MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disorders Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") today announces it has not made its payment obligations under its unsecured convertible... Read More

Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 12, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National... Read More

Global expansion as MYND executes non-binding MOU with German based Oxygen Handel. Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced it has entered into a non-binding memorandum... Read More

Identification of a potent, monomolecular non-hallucinogenic analog of psilocybin 100 times stronger than psilocybin. Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31, 2022 (the "2022 Financial Statements") prior to the filing deadline of... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ( " MYND " or the " Company "), a biopharmaceutical research and development company creating innovated and precision medicines for patients with relentless neurological diseases, is pleased to announce the disposition of the Company's leasehold agreement at 733 Finns Road, Kelowna with tenant improvements... Read More

Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) (" Mynd " or the " Company "), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological diseases, announces a stock option grant pursuant to the Company's stock option plan. Stock Option Grant The Company's Board of Directors has approved a stock options grant, exercisable... Read More

Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) (" Mynd " or the " Company ") announces that it has terminated the non-binding memorandum of understanding (" MOU ") to acquire all the issued and outstanding shares of Tidal Care Inc. o/a Tidal Psychedelics (" Tidal ") as disclosed in Mynds's March 16, 2022 press release, due to differences in the strategic direction of the proposed acquisition. Mynd has advised Tidal of... Read More

Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) (" Mynd " or the " Company "), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological diseases, is pleased to announce that Dr. Wilfred Jefferies, Mynd's Chief Scientific Officer, has been inducted as a Fellow of the National Academy of Inventors. Globally, the most... Read More